![]() |
市場調查報告書
商品編碼
1499536
大鼠和小鼠模型市場:按模型類型、技術、服務、治療領域和最終用戶分類 - 全球預測 2024-2030Rat & Mouse Model Market by Model Type, Technology, Service, Therapeutic Area, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
大鼠和小鼠模型市場規模預計2023年為22.7億美元,2024年達24.5億美元,預計2030年將達到39.7億美元,複合年成長率為8.26%。
大鼠和小鼠模型是生物醫學研究的基本工具,可作為研究人類生理、遺傳學、藥理學和疾病發病機制的類似物。這些模型是專門培育的囓齒動物,用於了解疾病機制、評估藥物的有效性以及評估遺傳對健康和疾病的貢獻。大鼠和小鼠模型的選擇是基於研究目的,每種模型在遺傳學、體型以及與人類的生理相似性方面都有自己的優勢。 CRISPR/Cas9技術和其他基因工程工具的創新顯著提高了創建基因改造大鼠和小鼠模型的準確性和效率。政府機構、非營利組織和私營部門對生物醫學研究活動(包括大鼠和小鼠模型的開發和使用)的資助大幅增加。然而,替代研究方法(例如晶片器官和電腦建模)的發展和改進可能會減少某些類型的研究對動物模型的依賴。此外,許多人類疾病是多因素且複雜的,因此很難在大鼠或小鼠模型中完全重現人類病理學。由於遺傳背景、環境條件和調查方法的差異,導致研究的可重複性變得複雜。領先的研究人員正在探索基因工程的進展,為創建更準確和疾病特異性的大鼠和小鼠模型提供了機會。將大鼠和小鼠模型與高通量定序和生物資訊學等新技術相結合,為詳細的遺傳分析和理解疾病機制開闢了新的途徑。
主要市場統計 | |
---|---|
基準年[2023] | 22.7億美元 |
預測年份 [2024] | 24.5億美元 |
預測年份 [2030] | 39.7億美元 |
複合年成長率(%) | 8.26% |
區域洞察
美洲,特別是美國和加拿大,擁有強大的生物醫學研究生態系統,並得到醫療保健和藥物研發 (R&D) 的大量投資的支持。這些地區的消費者正在影響他們對基因工程和 CRISPR 基因編輯模型的購買行為,因為他們優先考慮提供精確性和可重複性的模型。美國的研究計畫和專利重點關注基因工程、CRISPR 技術和個人化醫療應用的創新。美國國立衛生研究院 (NIH) 支持疾病建模研究,特別是癌症、神經退化性疾病和心血管疾病的研究。歐盟 (EU) 國家因其成熟的製藥和生物技術產業以及高標準的醫療保健研究而表現出對大鼠和小鼠模型的強烈需求。歐盟的監管框架和資助機制,包括“地平線歐洲”,促進了遺傳學、腫瘤學和神經退化研究的研究和創新。歐盟消費者的需求集中在研究中動物的道德採購和使用、促進替代方案以及大鼠和小鼠模型的有效使用。消費者運動受到嚴格指導方針的監管,以確保研究動物的福利和道德待遇。以中國、日本和印度為代表的亞太地區是大鼠模型發展最快的地區。支持這一成長的是對藥物研發、基因研究的投資增加以及對個人化醫療日益成長的興趣。中國市場得到了政府在生物技術和藥物開發領域的大量投資以及基因工程專業知識不斷成長的支持。日本擁有先進的醫療保健系統,並且專注於針對老齡化人口的創新治療,因此強調神經退化和心血管研究的模型。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在大鼠和小鼠模型市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢查了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對大鼠和小鼠模型市場中供應商的當前狀態進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在大鼠和小鼠模型市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[193 Pages Report] The Rat & Mouse Model Market size was estimated at USD 2.27 billion in 2023 and expected to reach USD 2.45 billion in 2024, at a CAGR 8.26% to reach USD 3.97 billion by 2030.
Rat & mouse models are fundamental tools in biomedical research, serving as analogs for studying human physiology, genetics, pharmacology, and disease pathogenesis. These models have specifically bred rodents used to understand disease mechanisms, assess drug efficacy, and evaluate genetic contributions to health and disease. The choice between rat and mouse models is determined based on the research objectives, with each offering unique advantages in terms of genetics, size, and physiological similarities to humans. Innovations in CRISPR/Cas9 technology and other genetic manipulation tools have significantly improved the precision and efficiency of creating genetically modified rat and mouse models. There is a substantial rise in funding from government bodies, non-profit organizations, and the private sector towards biomedical research activities, including the development and use of rat and mouse models. However, the development and improvement of alternative research methods, such as organ-on-a-chip and computer modeling, might reduce reliance on animal models for some types of research. Furthermore, many human diseases are multifactorial and complex, making it challenging to fully replicate human pathologies in rat and mouse models. Ensuring the replicability of the studies is complicated by variability in genetic backgrounds, environmental conditions, and methodological differences. Key players are exploring ongoing advancements in genetic engineering and offering opportunities to create more accurate and disease-specific rat and mouse models. Combining rat and mouse models with emerging technologies, such as high-throughput sequencing and bioinformatics, opens new avenues for in-depth genetic analysis and understanding of disease mechanisms.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.27 billion |
Estimated Year [2024] | USD 2.45 billion |
Forecast Year [2030] | USD 3.97 billion |
CAGR (%) | 8.26% |
Regional Insights
In the Americas, particularly in the United States and Canada, there is a robust ecosystem for biomedical research supported by substantial investments in healthcare and pharmaceutical research and development (R&D). Consumers in these regions prioritize models that offer precision and reproducibility, thus influencing purchasing behavior towards genetically engineered and CRISPR gene-edited models. Research initiatives and patents in the United States focus on innovations in genetic engineering, CRISPR technology, and personalized medicine applications. The National Institutes of Health (NIH) supports research in disease models, particularly for cancer, neurodegenerative diseases, and cardiovascular conditions. The European Union (EU) countries exhibit a strong need for rat and mouse models, driven by well-established pharmaceutical and biotech industries, alongside high standards for healthcare research. The EU's regulatory framework and funding mechanisms, including Horizon Europe, facilitate research and innovation in genetic, oncology, and neurodegenerative studies. Consumer demands in the EU focus on ethical sourcing and the use of animals in research, pushing for alternative methods and efficient use of rat and mouse models. Consumer dynamics is regulated by stringent guidelines that ensure the welfare and ethical treatment of research animals. The Asia Pacific region, led by China, Japan, and India, is a rapidly growing landscape for rat and mouse models. This growth is underpinned by increasing investments in pharmaceutical R&D, genetic research, and a rising focus on personalized medicine. China's market is propelled by significant government investment in biotechnology and drug development sectors, alongside growing expertise in genetic engineering. Japan, with its sophisticated healthcare system and a strong emphasis on innovative treatments for aging populations, places a premium on models for neurodegenerative and cardiovascular research.
Market Insights
The market dynamics represent an ever-changing landscape of the Rat & Mouse Model Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Rat & Mouse Model Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Rat & Mouse Model Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Enhancing Preclinical Research through Advanced Genetically Modified Mouse Models by Charles River Laboratories
Charles River Laboratories has significantly advanced its Triple-Immunodeficient Mouse Model Portfolio with the introduction of the NCG Plus series, focusing on enhancing preclinical research capabilities. The latest additions, NCG-hIL2 and NCG-hIL15, are engineered to express human cytokines, IL-2 and IL15, respectively, facilitating the expansion and activation of immune cells, crucial for in vivo studies. [Published On: 2024-01-11]
Innovative Mouse Model Paves Way for New Therapies in Chronic Lymphocytic Leukaemia and Richter Transformation
Researchers from Hospital Clinic-IDIBAPS have developed a groundbreaking mouse model that emulates the Richter transformation observed in chronic lymphocytic leukaemia (CLL) patients, marking a pivotal advancement in the pursuit of effective treatments for this aggressive lymphoma conversion. This transformative development hinges on the creation of patient-derived xenografts, employing cells from a CLL patient to establish the model that accurately represents the clinical progression and molecular dynamics of Richter transformation. [Published On: 2023-12-15]
Pioneering a Mouse Model to Elucidate the Role of IL-6 in Frailty and Aging
Johns Hopkins University School of Medicine researchers have advanced o understanding of frailty in aging mammals through the development of a novel mouse model. By genetically engineering middle-aged male mice to express the human IL-6 gene, the researchers have illuminated the complex effects of this protein on cellular mitochondria and overall physical decline. This innovative model offers a nuanced understanding of IL-6's dualistic role in inflammation and frailty, providing a valuable framework for future investigations into the molecular underpinnings of aging. [Published On: 2023-07-11]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Rat & Mouse Model Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Rat & Mouse Model Market, highlighting leading vendors and their innovative profiles. These include Allentown, Inc., Aragen Life Sciences, Biocytogen, Biomere Biomedical Research Models, Inc., Champions Oncology, Inc., Charles River Laboratories International, Inc., Crown Bioscience, Inc. by JSR Corp., Cyagen US Inc., Envigo by Inotiv, Inc., GemPharmatech, GenOway S.A., Harbour Biomed, Hera BioLabs, Ingenious Targeting Laboratory, Janvier Labs, Oncodesign Precision Medicine, Ozgene Pty Ltd., PerkinElmer, Inc., Pharmatest Services Oy, PolyGene AG, Taconic Biosciences, Inc., The Jackson Laboratory, TransCure Bioservices, TransViragen, Inc., and Vivo Bio Tech Ltd..
Market Segmentation & Coverage